Brought to you by 
Instead of Mylan, Teva opts for Allergan's generics business (Actavis Generics), paying $40.5bn, deal value later reduced to $38.8bn
01 Jun 2021
Executive Summary
Months after announcing a hostile bid to buy Mylan NV to create what could have been the second-leading generics company globally, Teva Pharmaceutical Industries Ltd. agreed to acquire Allergan PLC's generic business (Actavis Generics) for $40.5bn--$33.75bn in cash and $6.75bn in Teva stock. Concurrently, Teva officially withdrew its offer for Mylan, which had rejected it anyway. (Mylan is still pursuing its own hostile takeover of Perrigo.)
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Instead of Mylan, Teva opts for Allergan's generics business (Actavis Generics), paying $40.5bn, deal value later reduced to $38.8bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice